$1.03
-0.03 (-2.37%)
Open$1.06
Previous Close$1.06
Day High$1.08
Day Low$1.00
52W High$4.23
52W Low$1.18
Volume—
Avg Volume4.57M
Market Cap281.52M
P/E Ratio—
EPS$-1.57
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+3,763.1% upside
Current
$1.03
$1.03
Target
$39.79
$39.79
$29.42
$39.79 avg
$58.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 65.93M | 59.67M | 56.91M |
| Net Income | 10.90M | 11.06M | 10.11M |
| Profit Margin | 16.5% | 18.5% | 17.8% |
| EBITDA | 19.62M | 16.47M | 16.10M |
| Free Cash Flow | 6.94M | 6.70M | 7.67M |
| Rev Growth | +19.8% | +7.9% | +20.9% |
| Debt/Equity | 0.22 | 0.21 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $283.54 | -0.86% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $438.82 | -1.14% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $166.53 | -1.45% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $520.66 | -2.94% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $923.34 | -2.35% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $147.82 | -1.06% | 7.7 | 20.98B |